Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study.

ABSTRACT:

Background

Many patients who are on active surveillance (AS) for prostate cancer will have surveillance prostate needle biopsies (PNBs) without any cancer evident.

Objective

To define the association between negative surveillance PNBs and risk of reclassification on AS.

Design, setting, and participants

All men were enrolled in the Canary Prostate Active Surveillance Study (PASS) between 2008 and 2016. Men were included if they had Gleason ≤3+4 prostate cancer and <34% core involvement ratio at diagnosis. Men were prescribed surveillance PNBs at 12 and 24 mo after diagnosis and then every 24 mo.

Outcome measurements and statistical analysis

Reclassification was defined as an increase in Gleason grade and/or an increase in the ratio of biopsy cores to cancer to

SUBMITTER: Kearns JT 

PROVIDER: S-EPMC6064187 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature